Canada - English - Health Canada

taro pharmaceuticals inc - dasatinib - tablet - 70mg - dasatinib 70mg - antineoplastic agents

Canada - English - Health Canada

taro pharmaceuticals inc - dasatinib - tablet - 80mg - dasatinib 80mg - antineoplastic agents

Canada - English - Health Canada

taro pharmaceuticals inc - dasatinib - tablet - 100mg - dasatinib 100mg - antineoplastic agents

Canada - English - Health Canada

taro pharmaceuticals inc - dasatinib - tablet - 140mg - dasatinib 140mg - antineoplastic agents

New Zealand - English - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - rivastigmine 18mg;   - transdermal patch - 9.5 mg/24h - active: rivastigmine 18mg   excipient: acrylates copolymer acrylic adhesive fluoro-coated polyester release liner (22.5 cm2/patch) silicone adhesive - treatment of patients with: · mild to moderately severe dementia of the alzheimer's type (also termed probable alzheimer's disease or alzheimer's disease) · severe dementia of the alzheimer's type.

New Zealand - English - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - rivastigmine 27mg;   - transdermal patch - 13.3 mg/24h - active: rivastigmine 27mg   excipient: acrylates copolymer acrylic adhesive fluoro-coated polyester release liner (33 cm2/patch) silicone adhesive - treatment of patients with: · mild to moderately severe dementia of the alzheimer's type (also termed probable alzheimer's disease or alzheimer's disease) · severe dementia of the alzheimer's type.

New Zealand - English - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - rivastigmine 9mg;   - transdermal patch - 4.6 mg/24h - active: rivastigmine 9mg   excipient: acrylates copolymer acrylic adhesive fluoro-coated polyester release liner (14 cm2/patch) silicone adhesive - treatment of patients with: · mild to moderately severe dementia of the alzheimer's type (also termed probable alzheimer's disease or alzheimer's disease) · severe dementia of the alzheimer's type.

New Zealand - English - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - voriconazole 200mg - film coated tablet - 200 mg - active: voriconazole 200mg excipient: colloidal silicon dioxide croscarmellose sodium lactose magnesium stearate maize starch opadry white 33k18618 povidone pregelatinised maize starch - voriconazole is indicated for treatment of the following fungal infections: · invasive aspergillosis. · serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). · serious fungal infections caused by scedosporium spp. and fusarium spp. · other serious fungal infections, in patients intolerant of, or refractory to, other therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - voriconazole 50mg - film coated tablet - 50 mg - active: voriconazole 50mg excipient: colloidal silicon dioxide croscarmellose sodium lactose magnesium stearate maize starch opadry white 33k18618 povidone pregelatinised maize starch - voriconazole is indicated for treatment of the following fungal infections: · invasive aspergillosis. · serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). · serious fungal infections caused by scedosporium spp. and fusarium spp. · other serious fungal infections, in patients intolerant of, or refractory to, other therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

arrotex pharmaceuticals (nz) limited - entecavir monohydrate 0.532mg equivalent to 0.5 mg entecavir - film coated tablet - 0.5 mg - active: entecavir monohydrate 0.532mg equivalent to 0.5 mg entecavir excipient: magnesium stearate opadry white y-1-7000 silicified microcrystalline cellulose sodium starch glycolate - indicated for the treatment of chronic hepatitis b infection in adults with evidence of active liver inflammation.